# Tesamorelin Side Effects: What the Clinical Literature Reports > Tesamorelin side effects as documented in Phase III trials: injection-site reactions, arthralgias, fluid retention, and transient glucose changes. Safety evidence reviewed and cited. ## Most Common Adverse Events in Tesamorelin Clinical Trials The most frequently reported adverse events in clinical trials were: [1][2][3] - Injection-site reactions (erythema, pruritus, pain) - Arthralgias (joint pain) - Myalgias (muscle pain or aching) - Peripheral edema (fluid retention, typically mild) - Transient fasting glucose elevation ## Tesamorelin and Glucose Metabolism The pivotal Falutz 2007 NEJM trial found no significant change in fasting glucose in the 26-week treatment period. [1] The Falutz 2008 52-week extension similarly found no clinically significant glucose perturbation. [2] The prescribing information notes a small observed increase in fasting glucose (3–5 mg/dL mean) and a modest increase in the incidence of impaired fasting glucose in the Phase III trials. [1] The Clemmons 2017 trial in type 2 diabetes patients (n=53, 12 weeks, 1 or 2 mg/day) found no significant change in fasting glucose or HbA1c at either dose. [11] The 2026 meta-analysis of 5 RCTs confirmed no clinically significant glucose perturbation across pooled data. [16] ## Long-Term Safety Data from the 52-Week Extension Study Key long-term findings from Falutz 2008 and Falutz 2010: [2][3] - Adverse event profile at 52 weeks was consistent with 26-week data; no new safety signals emerged - Sustained VAT reductions (~18%) were maintained throughout the 52-week treatment period - IGF-1 levels remained elevated within a physiological range; monitoring was recommended - No clinically significant glucose worsening was observed in the controlled trial populations The 2024 INSTI-cohort trial confirmed that long-term safety findings extend to metabolically vulnerable patient populations with no glycemic worsening over 12 months. [17] ## Who Should Not Use Tesamorelin in Research Contexts? **Absolute contraindications:** [1][2] - Active malignancy - Pituitary tumor or structural pituitary damage - Pregnancy (animal studies showed fetal skeletal malformations and hydrocephaly at therapeutic doses) - Hypersensitivity to GHRH analogues or excipients **Precautions requiring monitoring:** - Pre-existing glucose dysregulation or diabetes [1][11] - Elevated baseline IGF-1 [2] - Prior malignancy: careful benefit-risk assessment required ## Drug Interactions Flagged in Tesamorelin Studies **Corticosteroids:** Glucocorticoids can blunt GH secretory response and may reduce the efficacy of tesamorelin. [1] **Insulin and anti-diabetic agents:** Co-administration may require dose adjustment or closer glucose monitoring. [11] No other significant drug-drug interactions are documented in the published trial literature. ## Tesamorelin and Hepatic Safety The NIH LiverTox database assigned tesamorelin a Likelihood Score of E (unlikely cause of clinically apparent liver injury), based on a prospective drug-injury surveillance study (n=899 enrolled cases) that attributed no cases of clinically apparent liver injury to tesamorelin. [19] Prospective trials specifically demonstrated hepatic fat reduction, not hepatic injury, as the liver-relevant outcome. [5][6] ## Tesamorelin and Malignancy No direct carcinogenicity was demonstrated in completed clinical trials. [1][2][3] The absolute contraindication for active malignancy reflects a precautionary principle based on the pharmacological mechanism, not on documented carcinogenicity. ## Safety Profile Summary - Most common adverse events: injection-site reactions, arthralgias, myalgias, peripheral edema - Metabolic: transient glucose elevation in some subjects; no significant HbA1c change in diabetic trial; cholesterol reduction in 2 mg diabetic group [11] - Hepatic: no hepatotoxicity signal; LiverTox Score E; ALT decreased in both groups across trials [19] - Long-term tolerance: 52-week and 12-month trial data indicate a sustained but consistent adverse event profile [2][17] - Contraindications: active malignancy, structural pituitary pathology, pregnancy, hypersensitivity - Monitoring: IGF-1 and glucose monitoring recommended throughout administration ## References [1] Falutz J, et al. N Engl J Med. 2007;357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/18057338/ [2] Falutz J, et al. AIDS. 2008;22(14):1719-28. https://pubmed.ncbi.nlm.nih.gov/18690162/ [3] Falutz J, et al. J Acquir Immune Defic Syndr. 2010;53(3):311-22. https://pubmed.ncbi.nlm.nih.gov/20101189/ [5] Stanley TL, et al. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/ [6] Stanley TL, et al. Lancet HIV. 2019;6(12):e821-e830. https://pubmed.ncbi.nlm.nih.gov/31611038/ [11] Clemmons DR, et al. PLoS One. 2017;12(6). https://pubmed.ncbi.nlm.nih.gov/28617838/ [16] Rousakis A, et al. Obes Res Clin Pract. 2026;20(1):2-12. https://pubmed.ncbi.nlm.nih.gov/41545261/ [17] Fourman LT, et al. AIDS. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11365754/ [19] National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin — LiverTox. 2020. https://www.ncbi.nlm.nih.gov/books/NBK548730/ [20] Fourman LT, et al. AIDS. 2017;31(16). https://pubmed.ncbi.nlm.nih.gov/28832410/ --- A peer-reviewed field record of the tesamorelin literature — FDA approvals, Phase III trials, and pharmacokinetics indexed here, not prescribed here.